MindMed (MMED.NE, MNMD.Q) announced the start of a Phase 1 trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT. DMT, properly known as N,N-Dimethyltryptamine is a psychoactive chemical…
Psychedelics
Braxia Scientific’s (BRAX.C) CEO Dr. Roger McIntyre and Chief Medical and Scientific Officer Dr. Josh Rosenblat have received $918,000 from the Canadian Institutes of Health Research (CIHR), the Government of Canada’s federal funding agency…
Mind Cure Health (MCUR.C) announced they have launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. MINDCURE will be assessing the quality of…
Psyched Wellness (PSYC.C) announced that they have completed extraction of AME-1 and have shipped it to their contract research organization in (CRO) partner labs in Asia. The AME-1 was…
Cybin (CYBN.NE) announced that they have received conditional approval to join the New York Stock Exchange (NYSE), specifically, the NYSE American LLC stock exchange. Cybin has reserved the ticker…
Mydecine Innovations (MYCO.NE) announced they are filing a new patent for their MDMA-like compounds. In the press release Mydecine writes that “this expansive patent would allow Mydecine to scale…
Tryp Therapeutics (TRYP.C) announced they plan to conduct a Phase 2a clinical trial with the Chronic Pain & Fatigue Research Center at the University of Michigan Medical School. The study will…
Braxia Scientific (BRAX.C) announced that they have established direct billing practices with Medavie Blue Cross for qualifying Canadian military veterans. This agreement is significant because it will allow 100%…
PsyBio Therapeutics (PSYB.V) announced it has filed a new provisional patent application with the US Patent and Trademark Office. The new patent is entitled Psilocybin and Norbaeocystin Compositions and…
Cybin (CYBN.NE) announced it has filed their 13th provisional patent application and is building out its digital therapeutics strategy. Cybin did not go into detail about the patent application,…